Verdura, S.;                     Encinar, J.A.;                     Fernández-Arroyo, S.;                     Joven, J.;                     Cuyàs, E.;                     Bosch-Barrera, J.;                     Menendez, J.A.    
        Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells. Int. J. Mol. Sci. 2022, 23, 9986.
    https://doi.org/10.3390/ijms23179986
    AMA Style
    
                                Verdura S,                                 Encinar JA,                                 Fernández-Arroyo S,                                 Joven J,                                 Cuyàs E,                                 Bosch-Barrera J,                                 Menendez JA.        
                Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells. International Journal of Molecular Sciences. 2022; 23(17):9986.
        https://doi.org/10.3390/ijms23179986
    
    Chicago/Turabian Style
    
                                Verdura, Sara,                                 José Antonio Encinar,                                 Salvador Fernández-Arroyo,                                 Jorge Joven,                                 Elisabet Cuyàs,                                 Joaquim Bosch-Barrera,                                 and Javier A. Menendez.        
                2022. "Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells" International Journal of Molecular Sciences 23, no. 17: 9986.
        https://doi.org/10.3390/ijms23179986
    
    APA Style
    
                                Verdura, S.,                                 Encinar, J. A.,                                 Fernández-Arroyo, S.,                                 Joven, J.,                                 Cuyàs, E.,                                 Bosch-Barrera, J.,                                 & Menendez, J. A.        
        
        (2022). Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells. International Journal of Molecular Sciences, 23(17), 9986.
        https://doi.org/10.3390/ijms23179986